Back to Dashboard







AstraZeneca PLC (AZN)
Real-time intraday values
Market Overview
From:
To:
AZN Intraday
No data available
SymbolAZN
IPO DateMay 12, 1993
CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Full Time Employees96.1k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited Kingdom
ExchangeNYSE
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.56% | -0.99 US$ |
| 5 Days | -5.44% | -10.03 US$ |
| 1 Month | +3.54% | +5.97 US$ |
| 6 Months | -6.74% | -12.61 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of AZN...
Key Statistics
Market Cap
270.40B
P/E Ratio
24.66
Div Yield
1.83%
52W High
$212.71
52W Low
$153.41
Analyst Consensus
ConsensusBuy
Bullish975.0%
Neutral216.7%
Bearish18.3%
52W Analyst Price Targets
Min Target
$158.00
$158.00
Max Target
$240.00
$240.00
Current$174.42
Avg Target$209.91
Analyst Recommendations
Target Price:$209.91($158.00 - $240.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on AZN
Join the community to share your analysis
Latest News for AZN
AstraZeneca leads European big pharma on growth, pipeline depth
Investing.com•Nov 20, 2026, 04:25 PM

FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
Zacks•Nov 20, 2026, 03:13 PM


Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Reuters•Nov 20, 2026, 11:09 AM
European shares tumble again as Anthropic debut fails to halt tech rout
Investing.com•Nov 20, 2026, 08:36 AM

Why AstraZeneca Could Make Sense Through ETFs Now
Simply Wall St.•Nov 19, 2026, 04:09 PM

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma Dive•Nov 19, 2026, 03:10 PM


AstraZeneca Says FDA Grants Priority Review to Sonesitatug Vedotin for Gastric, GEJ Cancers
MT Newswires•Nov 19, 2026, 09:41 AM